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Running Title: 
Renal angiotensinogen in diabetic nephropathy  
 
Abstract 
AIM. The renal renin-angiotensin system (RAS) has been implicated in the 
pathogenesis of diabetic nephropathy. The aim of this study was to investigate sex 
differences in renal renin-angiotensin system (RAS) and the roles of androgens in 
diabetes-associated renal injury.  
 
METHODS. Renal injury and fibrosis was studied in streptozotocin-induced diabetic 
rats by albuminuria and by gene expression of collagen-I and fibronectin. RAS was 
investigated by analyzing the plasma angiotensinogen (AOGEN) and renin activity 
(PRA) and their renal gene expression. Also, a group of diabetic rats was treated 
with the antiandrogen flutamide. 
 
RESULTS. Albuminuria was significantly lower in diabetic females than in males (1.2 
[0.8-1.5] vs. 4.4 [2.2-6.1] mg/24h, data are median [IQR] values, p<0.05). Renal 
AOGEN mRNA levels were increased by diabetes in males (8.1 ± 0.8 % in diabetes 
vs 0.8 ± 0.2 % in control, p< 0.001) but not in females (1.0 ± 0.1 % in diabetes vs 0.8 
± 0.1 % in control, p>0.05), as were collagen-I and fibronectin mRNAs. Furthermore, 
AOGEN mRNA levels were strongly correlated with albuminuria (Spearman r = 0.64, 
95%[CI] 0.36 to 0.81, p< 0.0001). Diabetes decreased PRA, renal renin mRNA and 
plasma AOGEN in both females and males. Antiandrogen treatment decreased 
albuminuria only in diabetic males without affecting the endocrine or renal RAS.  
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CONCLUSIONS. These data indicate that renal but not hepatic AOGEN or renin is 
positively associated with diabetic albuminuria and contribute to the sex-dependent 
differences in renal injury. Androgens may contribute to albuminuria in male 
independently of the RAS. 
Keywords: diabetes; renal angiotensinogen; albuminuria; androgens; sexual 
dimorphism  
 
Introduction 
The leading causes of chronic kidney disease are hypertensive nephropathy and 
diabetes. Novel therapeutic strategies are being explored to delay progression of 
chronic nephropathy to end-stage renal disease. Current knowledge indicates that 
an effective therapy would not only target a blood pressure lowering effect but also 
would have a direct tissue protective effect (Rashid and Mende, 2011). The generally 
accepted surrogate marker for chronic nephropathy is albuminuria. However, 
accumulating evidence is puzzling the predictive value of albuminuria in nephropathy 
development (Dronavalli et al., 2008). In fact, one third of patients with 
microalbuminuria have already renal functional decline (Perkins et al., 2007). 
Therefore, characterizing biomarkers that are implicated in the pathogenesis of 
chronic kidney disease is subject of contemporary investigations (Shlipak and Day, 
2013). The relationship between the renin-angiotensin system (RAS) and the 
progression of diabetic renal disease has been a subject of large investigation. A 
chronic overexpression of endocrine or paracrine RAS, localized in several 
cardiovascular organs, is considered to be an important contributor to the 
pathophysiology of chronic kidney disease (Campos et al., 2011, Baltatu et al., 2011, 
Skov et al., 2014). RAS inhibitors are utilized as first-line agents for hypertensive or 
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diabetic patients with progressive chronic kidney disease (Steckelings et al., 2011). 
Therapeutic efficacy of RAS inhibitors may importantly depend on the stage of 
disease progression, conditional on the pathological activation of endocrine and/or 
tissue RAS (Goncalves et al., 2011). Also, sexual dimorphisms have been observed 
in pathogenesis and treatment of chronic kidney disease induced by diabetes or 
hypertension (Kautzky-Willer et al., 2013, Baltatu et al., 2003).  
 
In the present study we aimed at investigating sex dependent differences in RAS 
associated with renal injury in diabetes. Possible correlations between RAS 
components and albuminuria, as surrogate marker of diabetic nephropathy were 
studied. Also, roles of androgens in diabetes-associated renal injury were explored 
through anti-androgen treatment.  
 
Methods 
All procedures complied with guidelines from the American Physiological Society, 
and institutional review board approved the study. 
 
Experimental diabetes-associated renal injury was studied in female and male rats 
Sprague-Dawley rats (6 weeks old) for 12 weeks after the injection of streptozotocin 
(65mg/kg, ip). DM was considered when glucose reached levels greater than 270 
mg/dL. Streptozotocin-diabetic rats may develop chronic kidney injury, while they are 
normotensive. To study the involvement of androgens in the development of diabetic 
renal injury, we treated them with flutamide (specific nonsteroidal competitive 
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antagonist of the androgen receptor, 30 mg/kg/day subcutaneously). Each 
investigational rat group comprised 6 rats. Rats were housed in groups of three in 
standard cages, synchronized to a 12-hour light–dark cycle, at ambient temperature 
23 ± 2°C. A standard rat diet and tap water were supplied ad libitum. 
 
Renal endpoints studied were albuminuria and gene expression of collagen I and 
fibronectin. Albuminuria was determined in 24 hours collected urine by 
Immundiagnostics (Bensheim, Germany) using a specific ELISA (Baltatu et al., 
2014). To evaluate kidney fibrosis, collagen I and fibronectin mRNA was determined 
by real-time RT-PCR SYBR-Green assay on 7500HT Fast Real-Time PCR System, 
using Power SYBR Green (Applied Biosystems, Foster City, California, USA). The 
variation in the amount of samples was normalized by parallel amplification with the 
target samples with ß-actin gene. Primer sequences were: 
 
collagen I F 5´-CTAGCCTCACACACTTAGTGATCTGC-3´; 
collagen I R 5´-CTAGGTGTGTGGGTGGCTTT-3´; 
fibronectin F 5'-CCCTCCATTTCTGAGTGGTC-3'; 
fibronectin R 5'-GACAGTGAGTCCTGTGGGGT-3'; 
ß-Actin F CCTCTGAACCCTAAGGCCAA; 
ß-Actin R AGCCTGGATGGCTACGTACA. 
 
The cycling conditions utilized in SYBR-Green assay were: 15 min at 950C of 
polymerase activation followed by 40 cycles of 3-step PCR consisting of 15 s at 950C 
of denaturation, 30 s for both 600C of annealing and 720C of extension. 
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Systolic blood pressure  (SBP) was measured in conscious rats by a non-invasive 
tail-cuff method using automated IN125/R in conjunction with PowerLab data 
acquisition systems and MLA5024 Rodent Restrainer (ADInstruments, NSW, 
Australia). 
 
Plasma renin activity (PRA) and angiotensinogen were determined in plasma 
obtained from trunk blood as previously described (Baltatu et al., 2002). The PRA 
was determined using a trapping immunoassay while AOGEN through 
radioimmunoassay. The renal gene expressions of renin and angiotensinogen were 
determined through real-time RT-PCR SYBR-Green assay. Primer sequences used 
were: 
 
Renin F 5´-GCTACATGGAGAATGGGACTGAA-3´; 
Renin R 5´-ACCACATCTTGGCTGAGGAAAC-3´; 
AOGEN F 5´-AGCACGGACAGCACCCTATT-3´; 
AOGEN R 5´-AGAACTCATGGAGCCCAGTCA-3´. 
 
Statistical Analysis 
Two-way analysis of variance (ANOVA) followed by Bonferroni's multiple 
comparisons test was performed using GraphPad Prism version 6.0e for Mac OS X, 
GraphPad Software, La Jolla California USA, www.graphpad.com. Comparisons 
between control female and male groups were by unpaired T test. P < 0.05 was 
considered to be statistically significant. 
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Results 
Renal end-points of diabetic renal injury and fibrosis.  
In experimental DM, while the levels of albuminuria were not significantly different 
within the female groups, those in male diabetic group were significantly higher than 
male control, and the Flutamide-treated male diabetic group was significantly 
different from the male control or diabetic groups (Figure 1.A.). Renal levels of 
collagen I (Figure 1.B.) and fibronectin (Figure 1.C.) mRNAs were not significantly 
different within the female groups, while those in male diabetic-untreated and 
Flutamide-treated diabetic groups were significantly higher than male control. 
Systolic blood pressure was significantly increased in male but not female diabetic 
rats in comparison with respective control groups (Figure 2). 
 
Plasma renin and angiotensinogen. 
Females had significantly lower PRA than males (Figure 3.A.). The PRA in both 
female and male diabetic-untreated and Flutamide-treated diabetic groups were 
significantly lower than respective control groups (Figure 3.A.). 
 
Females had significantly lower plasma angiotensinogen levels than males (Figure 
3.B.). The plasma angiotensinogen levels in both female and male diabetic-untreated 
and Flutamide-treated diabetic groups were significantly lower than respective 
control groups (Figure 3.A.). 
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Plasma renin activity or angiotensinogen levels in Flutamide-treated diabetic groups 
were not significantly different from the respective diabetic-untreated groups, neither 
in females nor in males.  
 
Renal renin and angiotensinogen. 
The renal renin mRNA levels in both female and male diabetic-untreated and 
Flutamide-treated diabetic groups were significantly lower than respective control 
groups (Figure 4.A.). 
 
Renal AOGEN mRNA levels were significantly increased by diabetes in males but 
not in females in comparison with the respective control non-diabetic groups (Figure 
4.B.).  
 
Correlations between renin-angiotensin system and the surrogate marker of diabetic 
nephropathy. 
Figure 5 shows correlations of albuminuria with renal AOGEN mRNA, renal renin 
mRNA, plasma AOGEN or PRA. Renal AOGEN mRNA levels were strongly 
correlated with albuminuria (Spearman r = 0.64, 95% confidence intervals [CI] 0.36 
to 0.81, p< 0.0001). On the opposite, plasma AOGEN had a weak negative 
correlation, while PRA and renal renin mRNA were significantly negative correlated 
with albuminuria. 
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Discussion 
The present findings provide evidence that renal but not hepatic AOGEN or renin is 
positively associated with diabetic albuminuria and may contribute to the sex-
dependent differences in diabetes-associated renal injury and fibrosis. Androgens 
may contribute to the aggravated diabetes-associated renal injury in males 
independently of the RAS. 
 
The pathogenesis of diabetic nephropathy is directed by a chronic activation of 
several local and systemic factors including RAS that are responsible for multiple 
mechanisms related to kidney injury (Dronavalli et al., 2008). A recent individual 
patient meta-analysis has challenged early changes in proteinuria as a surrogate 
end point for kidney disease progression (Inker et al., 2014). Moreover, MacIsaac et 
al. contested the usefulness of microalbuminuria in diabetic nephropathy and call for 
the development of “risk markers apart from those related to the traditional 
‘albuminuric pathway’ to renal impairment” (MacIsaac et al., 2014). Considering that 
the renal RAS plays a central role in the pathogenesis of chronic nephropathy such 
as induced by diabetes (Van Buren and Toto, 2013) and in consequence 
albuminuria, it appears reasonable to argue that an increase in renal 
angiotensinogen may precede albuminuria. Indeed, research from the Navar group 
indicates that urinary angiotensinogen may provide index of the activated intrarenal 
RAS as a predictive marker of chronic nephropathy (Kobori et al., 2013, Mills et al., 
2012). Saito et al. have further demonstrated that increased urinary angiotensinogen 
is precedent to increased urinary albumin in patients with type 1 diabetes (Saito et 
al., 2009, Kamiyama et al., 2012). In a study with patients with type 2 diabetes, 
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hypertension, and albuminuria, Persson et al. have concluded that urinary 
angiotensinogen is a marker of filtration barrier injury rather than intrarenal RAS 
activity (Persson et al., 2013). Besides, van den Heuvel et al. indicated that urinary 
renin more closely reflects renal RAS activity than urinary angiotensinogen in 
diabetes (van den Heuvel et al., 2011). This apparent contradiction may be because 
RAS components have been determined at different stages of the diabetic 
pathology. In the present study we determined both circulating levels of 
angiotensinogen, renin and their renal levels of gene expression. The renal 
angiotensinogen gene expression levels were strongly correlated with the levels of 
albuminuria. This was not the case for plasma angiotensinogen. On the opposite, the 
plasma renin activity and renal renin mRNA levels were inversely correlated with 
albuminuria. Hence, the present study provides further support for renal 
angiotensinogen as a good predictor of diabetic nephropathy. Further studies should 
investigate the evolution of endocrine vs renal RAS associated with the progression 
of disease, when complications such as hypertension occur (Persson et al., 2013, 
van den Heuvel et al., 2011).  
 
A sexual dimorphism on the progression of renal disease has become an area of 
active investigation (Silbiger and Neugarten, 2008, Neugarten, 2002). In diabetic 
people, men are at higher risk than women for microvascular complications, such as 
nephropathy (Abbate et al., 2012). The mechanisms responsible for this sexual 
dimorphism in diabetic pathology represent a subject of actual investigation 
(Nedungadi and Clegg, 2009). In our study, renal angiotensinogen synthesis was 
increased by diabetes in male but not female rats and was associated with 
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albuminuria and renal fibrosis only in males. Thus considering renal angiotensinogen 
as a marker of renal RAS activation (Kobori et al., 2013, Mills et al., 2012), it 
indicates that the renal RAS contribute to the sexual dimorphism met in diabetic 
renal injury.  
 
Since renin is downregulated in this incipient phase of diabetes, alternative pathways 
for angiotensinogen cleavage may be considered. Enzymes other than the 
juxtaglomerular renin may provide alternative pathways for angiotensin II, such as 
prorenin from collecting duct (Kang et al., 2008) and chymase (Park et al., 2013) 
(angiotensin I-degrading enzyme (Nishimura et al., 1996)), whose synthesis is also 
increased in diabetes. Another candidate is cathepsin L that belongs to the cathepsin 
family able to generate angiotensin II from angiotensinogen (Legedz et al., 2004, 
Watanabe et al., 1989) and that is localized in the proximal tubule (Bauer et al., 
2011). Besides, the Bauer group found cathepsin L strongly associated with the 
degree of renal injury and proposed it as a potential sex-specific biomarker for renal 
damage (Bauer et al., 2011). 
 
In the present study, androgen receptor blockade attenuated diabetes-induced 
albuminuria but not renal fibrosis. Besides androgens, female sexual hormone may 
also contribute to the development of diabetic end-organ injury because blocking 
estradiol synthesis in male diabetic rats lowers albuminuria and renal fibrosis 
(Manigrasso et al., 2011). Since estradiol is also natural ligand for androgen receptor 
(Yeh et al., 1998), the antialbuminuric effects of the receptor blockade in our study 
may inhibit the effects of both androgens and estrogens in males. The fact that the 
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renal anti-fibrotic effect was observed after inhibition of estradiol synthesis and not 
androgen receptor blockade may suggest that estrogen receptors localized in the 
mesangial cells of males (Irsik et al., 2013) may contribute to this effect. This 
appears to be in contrast to the renoprotective effects of estradiol in diabetic renal 
disease in females (Mankhey et al., 2005). Estrogen receptor could therefore count 
for the protection against end-organ injury in female diabetic rats. A possible 
interference between androgens and RAS was also investigated. In the present 
study, androgen blockade did not decrease an already declined renin activity and 
synthesis in diabetes, contrarily from malignant hypertension with overactive RAS 
and consequent renal end-organ injury (Baltatu et al., 2002, Baltatu et al., 2003).  
In summary, our study provides evidence for a sexual dimorphism in renal RAS 
activated in diabetes and further support the concept of renal angiotensinogen as an 
early biomarker in diabetic nephropathy. We envisage that further translational 
studies will advance our knowledge to further characterize urinary angiotensinogen 
in chronic nephropathy as a predictive biomarker. 
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Figure Legends 
Figure 1: Renal injury in experimental diabetes. (A) Albuminuria; (B) Renal 
collagen I mRNA levels; (C) Renal fibronectin mRNA levels. DM = diabetes mellitus 
group, DM_FLU = diabetes mellitus treated with flutamide group. Data are mean with 
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SEM; * p < 0.05 compared with the respective control group; # p < 0.05 compared 
with the DM_FLU group. 
Figure 2: Systolic blood pressure in experimental diabetes. DM = diabetes 
mellitus group, DM_FLU = diabetes mellitus treated with flutamide group. Data are 
mean with SEM; * p < 0.05 compared with the respective control group. 
Figure 3: Plasma renin activity (A) and angiotensinogen (B) in experimental 
diabetes. DM = diabetes mellitus group, DM_FLU = diabetes mellitus treated with 
flutamide group. Data are mean with SEM; * p < 0.05 compared with the respective 
control group and between the control groups of females and males. 
Figure 4: Renal renin (A) and angiotensinogen (B) gene expression in 
experimental diabetes. DM = diabetes mellitus group, DM_FLU = diabetes mellitus 
treated with flutamide group. Data are mean with SEM; * p < 0.05 compared with 
control group. 
Figure 5: Spearman’s rank correlations of albuminuria with: plasma renin activity 
(PRA), plasma angiotensinogen (AOGEN), renal renin mRNA levels and renal 
AOGEN mRNA levels; plotted data are Spearman’s ρ coefficient with 95% 
confidence intervals. * p (two-tailed) < 0.05. 
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